Summary
Abstract
Sustained release bupropion (amfebutamone) is a non-nicotine agent that is indicated as an aid to smoking cessation.
In 2 large well designed clinical trials, sustained release bupropion 300 mg/day (the recommended dose) for 7 or 9 weeks was associated with considerably and significantly higher smoking abstinence rates (continuous abstinence and 7-day point prevalence rates) than placebo during treatment and at follow-up at 6 and 12 months. Point prevalence rates at 12 months in 2 studies were 23.1 and 30.3% with bupropion, whereas values for placebo were 12.4 and 15.6%. Continuous abstinence rates at 12 months, available from 1 trial, were 18.4% with bupropion and 5.6% with placebo. Furthermore, bupropion was associated with significantly higher quitting rates than nicotine patch in a comparative study. Combination therapy with bupropion and nicotine patch provided slightly higher abstinence rates than bupropion alone, although differences were not statistically significant. The combination was superior to nicotine patch alone.
Data from a preliminary report of long term bupropion treatment (52 weeks) showed that the drug was associated with significantly higher continuous abstinence rates than placebo only to 6 months. However, point prevalence abstinence rates were significantly higher with bupropion than placebo to 18 months.
Bupropion 300 mg/day recipients reported nicotine withdrawal symptoms during treatment; however, the symptoms were significantly less severe with bupropion than placebo. Patients receiving bupropion 300 mg/day or bupropion in combination with nicotine patch for smoking cessation generally gained less body weight than placebo recipients. The benefits of bupropion for preventing weight gain persisted after the completion of long term, but not short term therapy.
Bupropion was well tolerated in clinical trials, and the only adverse events that were significantly more common with bupropion than placebo were insomnia and dry mouth. Data published so far suggest that sustained release bupropion has a low potential for inducing seizures (seizure rate ≈0.1% in patients with depression).
Conclusions: Bupropion is an effective and well tolerated smoking cessation intervention. Further studies with long term follow-up will be useful in determining whether abstinence rates are maintained with bupropion. In addition, clarification of its efficacy in comparison with other therapies used for smoking cessation would help to establish its clinical value. The reduced potential for weight gain with bupropion and the ability to use bupropion in combination with nicotine replacement therapy make the drug a useful treatment option for smoking cessation.
Pharmacology
The mechanism by which bupropion (amfebutamone) acts as an aid in smoking cessation is unknown. However, bupropion is thought to produce its therapeutic antidepressant effects via the inhibition of noradrenaline and/or dopamine reuptake. Bupropion does not affect serotonin reuptake.
Bupropion showed dependence potential in animal models, but not at therapeutic dosages in individuals who abuse drugs or in healthy volunteers. Post-marketing surveillance data have shown that bupropion has a very low abuse potential.
Maximum plasma concentrations of sustained release bupropion are reached approximately 3 hours after an oral 150mg dose. Bupropion is highly plasma protein bound, and is extensively metabolised to 3 active metabolites. A single 150mg dose of sustained release bupropion has a mean elimination half-life of 18 to 19 hours. Around 84% and 9% of an oral dose of bupropion was recovered in the urine and faeces, respectively, within 72 hours after administration.
There is little available data on the effects of the concomitant administration of bupropion and other drugs on the metabolism of each drug. However, there is potential for interactions between bupropion and drugs that affect the cytochrome P450 (CYP) 2B6 isoenzyme. In addition, bupropion inhibits the activity of the CYP2D6 isoenzyme, which metabolises certain antidepressants (including tricyclic antidepressants and selective serotonin reuptake inhibitors), β-blockers, antiarrhythmics and antipsychotics. It is recommended that coadministration of bupropion and such drugs is approached with caution.
There are no significant differences in the pharmacokinetics of sustained release bupropion between smokers and nonsmokers. Sustained release bupropion is bioequivalent to the immediate release formulation in humans.
Therapeutic Efficacy
Sustained release bupropion 300 mg/day for 7 or 9 weeks significantly increased smoking cessation rates (continuous abstinence and 7-day point prevalence rates) during treatment and at follow-up at 6 and 12 months versus placebo in 2 large well designed studies. Point prevalence rates at 12 months were ≤30.3% with bupropion, whereas values for placebo were ≤15.6%. In 1 trial, continuous abstinence rates at 12 months were 18.4% with bupropion and 5.6% with placebo. Furthermore, bupropion was associated with significantly higher quitting rates than nicotine patch in the only comparison. Combination therapy with bupropion and nicotine patch provided slightly higher abstinence rates than bupropion alone, although differences were not statistically significant. The combination was superior to nicotine patch alone.
Data from a preliminary report of long term bupropion treatment (52 weeks) showed that the drug was associated with significantly higher continuous abstinence rates than placebo only to 6 months. However, point prevalence abstinence rates were significantly higher with bupropion than placebo to 18 months.
Bupropion 300 mg/day recipients reported significant withdrawal symptoms during treatment; however, the symptoms were significantly less with bupropion than placebo. In the preliminary report of a long term (52 weeks’ treatment) study, bupropion recipients had significantly less craving for cigarettes than placebo recipients and craving was less likely to be the reason for relapse with bupropion than placebo.
Bodyweight gain was generally less in patients receiving bupropion 300 mg/day or bupropion in addition to nicotine patch for smoking cessation than in placebo recipients. The benefits of bupropion for preventing weight gain persisted after the completion of long term, but not short term therapy.
Tolerability
Short term treatment with sustained release bupropion 300 mg/day was well tolerated in clinical trials of the drug for smoking cessation. The only adverse events that were significantly more common with bupropion than placebo were insomnia and dry mouth. Sustained release bupropion appears to have a lower propensity to cause seizures than the immediate release formulation (≈0.1 vs 0.4% for therapeutic dosages); however, no direct comparison of seizure rates between the formulations has been made.
Immediate release bupropion was generally well tolerated in patients with pre-existing heart disease. The cardiovascular effects of bupropion have not been assessed in patients with unstable heart disease or recent myocardial infarction, although studies are ongoing.
Dosage and Administration
It is recommended that sustained release bupropion 300 mg/day (twice daily) is given for 7 to 12 weeks for smoking cessation in adults. A target quitting date should generally be set for within the first 2 weeks of treatment. Patients are able to continue smoking while they take bupropion. In patients requiring continuous treatment, bupropion can be continued for up to 6 months (US) or a year (Canada). Bupropion can be given with transdermal nicotine. Patients with hepatic or renal disease should be treated with reduced dosages of bupropion.
Bupropion is contraindicated in patients with bulimia or anorexia nervosa and in patients with seizure disorders. In addition, bupropion should be given with caution to patients with risk factors for seizures. Mothers should not continue breastfeeding infants while taking bupropion.
Similar content being viewed by others
References
Miller NS, Cocores JA, Belkin B. Nicotine dependence: diagnosis, chemistry and pharmacological treatments. Ann Clin Psychiatry 1991 Mar; 3: 47–53
Goldstein MG. Bupropion sustained release and smoking cessation. J Clin Psychiatry 1998; 59 Suppl. 4: 66–72
Lee EW, D’Alonzo GE. Cigarette smoking, nicotine addiction, and its pharmacologie treatment. Arch Intern Med 1993 Jan 11; 153: 34–48
Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 1988 Nov 17; 319(20): 1318–30
Pontieri FE, Tanda G, Orzi F, et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996 Jul 18; 382: 255–7
Rose JE. Nicotine addiction and treatment. Annu Rev Med 1996; 47: 493–507
Sherwood N. Effects of nicotine on human psychomotor performance. Hum Psychopharm 1993 May–Jun; 8: 155–84
Clarke PBS. Nicotine dependence — mechanisms and therapeutic strategies. Biochem Soc Symp 1994; 59: 83–95
Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995 Nov 2; 333: 1196–203
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
Anda RF, Williamson DF, Escobedo LG, et al. Depression and the dynamics of smoking: a national perspective. JAMA 1990 Sep 26; 264(12): 1541–5
Glassman AH, Heizer JE, Covey LS, et al. Smoking, smoking cessation and major depression. JAMA 1990 Sep 26; 264(12): 1546–9
Glassman AH, Stetner F, Walsh BT, et al. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA 1988; 259(19): 2863–6
Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. Am J Psychiatry 1992 Apr; 149(4): 464–9
Ferry LH, Schopper V. Bupropion and nicotine replacement therapy for smoking cessation in an open clinical trial [abstract]. J Invest Med 1996 Jan; 44: 120
Ferry LH, Robbins AS, Scariati PD, et al. Enhancement of smoking cessation using the antidepressant, bupropion hydro-chloride [abstract]. Circulation 1992 Oct; 86 Suppl.: I–671
Bupropion hydrochloride. In: PDR Generics. 4th ed. Montvale: Medical Economics Company, 1999: 400–7
Ascher JA, Cole JO, Colin J-N, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995 Sep; 56: 395–401
Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51: 237–54
Lamb RJ, Griffiths R. Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology 1990; 102(2): 183–90
Griffith JD, Carranza J, Griffith C, et al. Bupropion: clinical assay for amphetamine-like abuse potential. J Clin Psychiatry 1983 May; 44 (5 Pt 2): 206–8
Miller L, Griffith J. A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology 1983; 80(3): 199–205
Peck AW, Bye CE, Clubley M, et al. Acomparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects. Br J Clin Pharmacol 1979; 7: 469–78
Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol 1998; 6(1): 32–44
Ahluwalia JS, Winter PD, Tucker VL. Summary of safety profile of bupropion HCl (Zyban) [poster]. Society for Research on Nicotine and Tobacco; 1999 Nov 25–26; London
Hsyu P-H, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997 Aug; 37: 737–43
Findlay JWA, Van Wyck Fleet J, Smith PG, et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981; 1981: 127–35
Briggs GG, Samson JH, Ambrose PJ, et al. Excretion of bupropion in breast milk. Ann Pharmacother 1993 Apr; 27: 431–3
Wurm RM, Dunn JA, Silver IS, et al. In vitro metabolism of bupropion by human liver microsomes and cDNA expressed human cytochrome P450’s [abstract]. 7th ISSX 1996 Oct 20; 10: 371
Goodale E, Ascher J, Batey S. Cytochrome P450 metabolism of bupropion [abstract]. J Am Geriatr Soc 1999 Sep; 47(9): S88
Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983; 44(5): 79–81
DeVane CL, Laizure SC, Stewart JT, et al. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990 Oct; 10: 328–32
Glaxo Wellcome. Bupropion hydrochloride sustained-release tablets prescribing information. Research Triangle Park, North Carolina, US, 1999
Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995 Oct; 15: 327–33
Popli AP, Tanquary J, Lamparella V, et al. Bupropion and anti-convulsant drug interactions. Ann Clin Psychiatry 1995 Jun; 7: 99–101
Shad MU, Preskorn SH. A possible bupropion and imipramine interaction [letter]. J Clin Psychopharmacol 1997 Apr; 17(2): 118–9
Posner J, Bye A, Jeal S, et al. Alcohol and bupropion pharmacokinetics in healthy male volunteers. Eur J Clin Pharmacol 1984; 26: 627–30
Corrigan B, Hsyu PH, Kustra R, et al. Arandomized, crossover study to evaluate the pharmacokinetic effect of cimetidine on Wellbutrin (bupropion HCl) sustained release in healthy subjects [abstract]. Pharm Res 1997; 14(11): S560
Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997 Oct 23; 337: 1195–202
Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999 Mar 4; 340: 685–91
Hayford KE, Patten CA, Rumman TA, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999 Feb; 174: 173–8
Hays JT, Hurt RD, Wolter TD, et al. Bupropion-SR for relapse prevention [abstract]. Sixth Annual Conference of the Society for Research on Nicotine and Tobacco; 2000 Feb 18–20; Arlington, Virginia
Rigotti NA, Thorndike AN, Durcan MJ, et al. Post-cessation weight gain in smokers taking bupropion: the effect of gender [abstract]. Sixth Annual Conference of the Society for Research on Nicotine and Tobacco; 2000 Feb 18–20; Arlington, Virginia
Gonzales D, Bjornson WM, Durcan MJ, et al. Effects of gender on smoking cessation and relapse rates in smokers treated with bupropion SR [abstract]. Sixth Annual Conference of the Society for Research on Nicotine and Tobacco; 2000 Feb 18–20; Arlington, Virginia
Durcan MJ, Deener G, White JD, et al. Factors associated with relapse: lessons from a bupropion SR relapse-prevention trial [poster]. Sixth Annual Conference of the Society for Research on Nicotine and Tobacco; 2000 Feb 18–20; Arlington (VA)
Velicer WF, Prochaska JO, Rossi JS, et al. Assessing outcome in smoking cessation studies. Psychol Bull 1992; 111(1): 23–41
Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991 Apr; 148: 512–6
Farid FF, Wenger TL, Tsai SY, et al. Use of bupropion in patients who exhibit orthostatic hypotension on tricyclic antidepressants. J Clin Psychiatry 1983; 44 (5 Pt 2): 170–3
Patten CA, Rummans TA, Croghan IT, et al. Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports. J Clin Psychiatry 1999 Jul; 60: 436–41
Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998 Jul; 59: 366–73
Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991 Nov; 52: 450–6
Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999; 11(4): 205–15
Croft H, Settle E Jr, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999 Apr; 21: 643–58
Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997 Dec; 58: 532–7
Tripathi A, Greenberger PA. Bupropion hydrochloride induced serum sickness-like reaction. Ann Allergy Asthma Immunol 1999 Aug; 83: 165–6
Yolles JC, Armenia WA, Alao AO. Serum sickness induced by bupropion. Ann Pharmacother 1999 Sep; 33: 931–3
David D, Esquenazi J. Rhabdomyolysis associated with bupropion treatment. J Clin Psychopharmacol 1999 Apr; 19: 185–6
Humma LM, Swims MP. Bupropion mimics a transient ischemic attack. Ann Pharmacother 1999 Mar; 33: 305–7
Labbate LA. Bupropion-SR-induced increased libido and spontaneous orgasm [letter]. Can J Psychiatry 1998 Aug; 43 (6)
Harmon T, Kurta D, Krenzelok EP. Delayed seizures from sustained-release bupropion overdose [abstract]. J Toxicol Clin Toxicol 1998; 36(5): 522
Shrier M, Díaz JE, Tsarouhas N. Cardiotoxicity associated with bupropion overdose [letter]. Ann Emerg Med 2000; 35 (1)
Paris PA, Saucier JR. ECG conduction delays associated with massive bupropion overdose. J Toxicol Clin Toxicol 1998; 36(6): 595–8
Weiner A, Nowicki T, Bayer M, et al. Zyban (bupropion) overdose [abstract]. J Toxicol Clin Toxicol 1998; 36(5): 521–2
Spiller HA, Ramoska EA, Krenzelok EP, et al. Bupropion in overdose: a 3-year multi-center retrospective analysis. Am J Emerg Med 1994; 12: 43–5
Glaxo Wellcome. Zyban® Product Monograph. Ontario, Canada (1998)
Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the health care system. Thorax 1998; 53 Suppl. 5
Haxby DG. Treatment of nicotine dependence. Am J Health Syst Pharm 1995; 52(3): 265–81
Cinciripini PM, McClure JB. Smoking cessation: recent developments in behavioral and pharmacologic interventions. Oncology Huntingt 1998 Feb; 12: 249–59
Peto R. Smoking and death: the past 40 years and the next 40. BMJ 1994 Oct 8; 309: 937–9
World Health Organization Regional Office for Europe. Economic Consequences of Smoking model. [online]. World Health Organization; 2000. Available from: URL: http://www.who.dk/adt/ecos/whoweb.asp [Accessed 2000 Feb 9]
Cohen S, Lichtenstein E, Prochaska JO, et al. Debunking myths about self-quitting. Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves. American Psychologist 1989; 44(11): 1355–65
Warner KE. Cost effectiveness of smoking-cessation therapies: interpretation of the evidence and implications for coverage. Pharmacoeconomics 1997 Jun; 11: 538–49
Smoking Cessation Clinical Practice Guideline Panel and Staff. The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA 1996 Apr 24; 275(16): 1270–80
Jorenby DE, Keehn DS, Fiore MC. Comparative efficacy and tolerability of nicotine replacement therapies. CNS Drugs 1995 Mar; 3: 227–36
Hughes JR. Non-nicotine pharmacotherapies for smoking cessation. J Drug Dev 1994 Jun; 6: 197–203
Benowitz NL. Treating tobacco addiction — nicotine or no nicotine? N Engl J Med 1997 Oct 23; 337: 1230–1
Hughes JR, Goldstein MG, Hurt RD, et al. Recent advances in the pharmacotherapy of smoking. JAMA 1999 Jan 6; 281: 72–6
Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994; 271(24): 1940–7
Silagy C, Mant D, Fowler G, et al. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 353(8890): 139–42
Williamson DF, Madans J, Anda RF, et al. Smoking cessation and severity of weight gain in a national cohort. New Engl J Med 1991; 324(11): 739–45
Bradley PS, Maddox RR, North WK. Bupropion SR with phentermine for weight reduction [abstract]. American Psychiatric Association 1999 Annual Meeting; 1999 May 15–20; Washington, DC
Gadde KM, Logue EJ. Bupropion sustained release in obesity: a randomized double-blind, placebo-controlled study [abstract]. American Psychiatric Association 1999 Annual Meeting; 1999 May 15–20; Washington, DC
de Wit H, Zacny J. Abuse potential of nicotine replacement therapies. CNS Drugs 1995 Dec; 4: 456–68
Author information
Authors and Affiliations
Corresponding author
Additional information
Various sections of the manuscript reviewed by: N.L. Benowitz, Division of Clinical Pharmacology and Experimental Therapeutics, University of California San Francisco, San Francisco, California, USA; M.C Fiore, Center for Tobacco Research and Intervention, University of Wisconsin Medical School, Madison, Wisconsin, USA; J.E. Henningfield, Pinney Associates, Bethesda, Maryland, USA; D.E. Jorenby, Center for Tobacco Research and Intervention, University of Wisconsin Medical School, Madison, Wisconsin, USA; R. Olmstead, Nicotine Research Unit, West Los Angeles Veterans Affairs Medical Center, Los Angeles, California, USA; M.A.H. Russell, Institute of Psychiatry, Tobacco Research Section, National Addiction Centre, London, England; P. Tønnesen, Department of Pulmonary Medicine, Gentofte University Hospital, Copenhagen, Denmark.
Data Selection
Sources: Medical literature published in any language since 1966 on bupropion, identified using AdisBase (a proprietary database of Adis International, Auckland, New Zealand), Medline and EMBASE. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.
Search strategy: AdisBase search terms were ‘bupropion’ or ‘amfebutamone’ and (‘smoking-cessation’ or ‘drug-dependence’ or ‘drug-withdrawal’ or ‘nicotine’ or ‘cigarette’). Medline search terms were ‘bupropion’ or ‘amfebutamone’ and (‘smoking-and-smoking-related-phenomena’ or ‘smoking’ or ‘nicotine’ or ‘tobacco’ or #x2018;cigarette’). EMBASE search terms were ‘bupropion’ or ‘amfebutamone’ and (‘smoking-cessation’ or ‘smoking’ or ‘nicotine’ or ‘cigarette’). Searches were last updated 22 February 2000.
Selection: Studies of sustained release bupropion for smoking cessation. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.
Index terms: bupropion, smoking cessation, pharmacodynamics, pharmacokinetics, therapeutic use.
Rights and permissions
About this article
Cite this article
Holm, K.J., Spencer, C.M. Bupropion. Drugs 59, 1007–1024 (2000). https://doi.org/10.2165/00003495-200059040-00019
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200059040-00019